CTRI/2016/11/007509已完成1 期
An Open Label, Phase I Study To Determine the Safety, Tolerability and Pharmacodynamics of Multiple Ascending Doses of PMZ-1620 in healthy male volunteers.
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 7
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Age: 18-60 yr old, both inclusive
- •Having a Body Mass Index (BMI) between 18.5-28 kg/m2 (both inclusive) and body weight not less than 45 kg
- •Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; and to comply with the requirements of the entire study
- •Voluntarily given written informed consent to participate in this study
- •Be of normal health as determined by the principal investigator from medical history, physical examination and laboratory investigations, 12-lead ECG and chest X-ray of the subjects performed within 10 days prior to the admission of the study
- •Ability and willingness to abstain from alcohol, methylxanthine-containing beverages or food (coffee, tea, coke, chocolate, power drinks) and grapefruit (juice) from 48 h prior to each admission until study completion.
排除标准
- •Employees of Clinical site or Pharmazz India Private Limited
- •Not willing to use contraceptives (preferably condoms) during sexual activity for the period of 3 months from the date of check-in
- •History of hypersensitivity and/or intolerance to PMZ-1620 or any other related compounds.
- •History of anaphylaxis to drugs or allergic reactions in general, which the Investigator considers may affect the outcome of the study.
- •Clinically abnormal ECG and Chest X-ray.
- •Physical findings: clinically relevant abnormal physical findings (including body temperature) suggesting underlying pathologies or those which could interfere with the objectives of the study.
- •Subjects with impaired renal function as measured by glomerular filtration rate <90 mL/min/1.73m2 estimated using the modification of diet in renal disease (MDRD) formula .
- •Laboratory values that are significantly different than the normal reference range and/or are deemed to be of clinical significance by the investigator
- •Presence of reactive disease markers of HIV 1 and II, HBsAg, HCV or VDRL.
- •Positive for alcohol breath test and/or urine drug screen (barbiturates, benzodiazepines, amphetamine, cocaine, opiates, tetra-hydro cannabinol).
- •Any evidence of organ dysfunction or any clinically significant deviation from the normal, in physical or clinical determinations.
- •Diseases: relevant history of renal, hepatic, cardiovascular, respiratory, skin, haematological, endocrine, neurological or gastrointestinal diseases. History of depression, psychosis, schizophrenia or any other severe psychiatric diseases, or epilepsy, or any other illness that may interfere with the aim of the study. History of any significant illness in the 4 weeks preceding the screening
- •Medications: history of intake of any medications including over the counter medications (OTC) and any herbal agents at least 4 weeks period prior to IP administration.
- •Investigational drug trials: participation in the evaluation of any drug in the 3 months prior to the start of the study (dosing with IMP).
- •Blood donation: Subjects who, through completion of this study, would have donated and/or lost more than 300 mL of blood in the past 12 weeks
- •Note: In case the blood loss is <= 200 mL; subject may be dosed 60 days after blood donation or last sample of the previous study
- •Regular smokers who smoke more than 10 cigarettes daily or have difficulty abstaining from smoking for the duration of each study period.
- •History of drug dependence or alcoholics.
研究者
相似试验
已完成
不适用
An Open-label, Phase I Study to determine the Safety and Pharmacokinetics of JNJ-26483327, a Multi-targeted Kinase Inhibitor, administered to Subjects with Advanced Stage and/or Refractory Solid Malignancies10027655cancerNL-OMON29756Johnson & Johnson Pharmaceutical50
已完成
不适用
An open label, phase 1 study to evaluate the safety, feasibility and immunogenicity of an allogeneic, cell-based vaccine (DCP-001) in high grade serous ovarian cancer patients after primary treatmentOverian carcinoma1003859410033283ovarian cancerNL-OMON55212niversitair Medisch Centrum Groningen17
进行中（未招募）
1 期
A Phase 1 clinical trial to test the safety, preliminary effects of increasing doses of AZD7648 alone and in combination with other anti-cancer agents in patients with advanced cancers..Advanced MalignanciesMedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003688-73-GBAstraZeneca AB230
已完成
1 期
An Open label Phase I Study to Evaluate the Safety and Efficacy of OBP-301 with Pembrolizumab in Patients with advanced solid tumors.solid tumorJPRN-UMIN000026961ational Cancer Center Hospital East22
已完成
1 期
A Phase 1, Open-label Study to Determine the Safety, Tolerability, and Pharmacokinetics of Multiple Subcutaneous Doses of Pentosan Polysulfate Sodium (PPS) in Healthy Adult ParticipantsBone Marrow LesionMusculoskeletal - OsteoarthritisMusculoskeletal - Other muscular and skeletal disordersInflammatory and Immune System - Other inflammatory or immune system disordersKnee OsteoarthritisACTRN12620000829910Paradigm Biopharmaceuticals Pty Ltd23